A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the effect of two dose strengths of
dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable
walking deficits in subjects with post-ischemic stroke.